Characteristics and survival of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
Keywords:
Breast cancer, Receptor ErbB-2, Neoplasm Metastasis, SurvivalAbstract
Introduction: There are multiple risk factors associated with the prognosis of survival of metastatic breast cancer (MBC). The two major risk factors are the expression of hormonal receptors (HR) and HER 2 neu, and the reason why they are requested in every MBC patient. The large majority (80%) of breast tumours are HR positive, and 20% are HER 2 positive. The aim of this study was to determine the prognostic factors associated with the overall survival (OS) of patients diagnosed with HER 2 positive MBC seen between January 2009 and December 2015 in the Instituto de Cancerología (Medellín-Colombia).
Methods: A retrospective observational study was conducted, with survival analysis using the Kaplan-Meier method. The survival curves were compared using the Log-Rank Test, and factors associated with survival were analysed using the Cox regression.
Results: 101 patients were included in the study. The median survival time was 46.6 months (Range 13-155 months), the 5-year OS was 41% (95% CI; 31%-50%) and the 10-year OS 13% (95 CI; 4%-30%). Higher overall survival was found for patients with relapsed disease, those with stages I and II, patients older than 40 years, postmenopausal, tumours with low histological grade and with co-expression of hormonal receptors. The patients with relapse of disease had a higher OS than the de novo patients after being adjusted for the other factors (HR: 0.47, 95% CI; 0.27-0.1).
Discussion: The overall survival time is similar to that of other countries, as well as the lines of treatment and therapy received.
Author Biographies
María Elvira Montoya-Restrepo, IDC-Instituto de Cancerología Las Américas
Instituto de Cancerología Las Américas, Grupo de Investigación en Cáncer IDC-Instituto de Cancerología Las Américas, Medellín, Colombia
Luis Rodolfo Gómez Wolff, Instituto de Cancerología Las Américas
Instituto de Cancerología Las Américas, Facultad de Medicina, Universidad de Antioquia, Grupo de Investigación en Cáncer IDC-Instituto de Cancerología Las Américas, Medellín, Colombia
Astrid Viviana Sánchez Jiménez, Instituto de Cancerología Las Américas
Instituto de Cancerología Las Américas, Grupo de Investigación en Cáncer IDC-Instituto de Cancerología Las Américas, Medellín, Colombia
Héctor Iván García García, Instituto de Cancerología Las Américas
Instituto de Cancerología Las Américas, Facultad de Medicina, Universidad de Antioquia, Grupo de Investigación en Cáncer IDC-Instituto de Cancerología Las Américas, Medellín, Colombia
References
Cuenta de Alto Costo. Situación del Cáncer en la población adulta atendida en el SGSSS de Colombia 2016. Disponible en: https://cuentadealtocosto.org/site/images/Situaci%C3%B3ndel c%C3%A1ncer_en_Colombia 2016-I.pdf.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide [base de datos en Internet]. International Agency for Research on Cancer; [acceso 21 Noviembre 2017]. Disponible en: http://globocan.iarc.fr.
Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013;119: 1140-8.
https://doi.org/10.1002/cncr.27819
Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann SurgOncol. 2013;20:2828-34.
https://doi.org/10.1245/s10434-013-2998-2
Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
https://doi.org/10.1016/S0140-6736(05)66544-0
Zeichner SB, Herna S, Mani A, Ambros T, Montero AJ, Mahtani RL, et al. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat. 2015;153:617-24.
https://doi.org/10.1007/s10549-015-3564-3
Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;21:2169-74.
https://doi.org/10.1093/annonc/mdq220
Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973-9.
https://doi.org/10.1002/cncr.22867
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.
https://doi.org/10.1056/NEJM200103153441101
Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer-asystematic review. Breast Cancer Res. 2015;17:140.
https://doi.org/10.1186/s13058-015-0648-2
Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and Trastuzumab treatment: an institutional-based review. J ClinOncol. 2010;28:92-8.
https://doi.org/10.1200/JCO.2008.19.9844
Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol. 2011;22:1308-17.
https://doi.org/10.1093/annonc/mdq593
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91.
https://doi.org/10.1056/NEJMoa1209124
Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, et al. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. The Breast. 2014;23:44-9.
https://doi.org/10.1016/j.breast.2013.10.005
Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. The Breast. 2013;22:525-31.
https://doi.org/10.1016/j.breast.2012.12.006
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J ClinOncol. 2013;31:3997-4013.
https://doi.org/10.1200/JCO.2013.50.9984
Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-72.
Letón E, Zuluaga P. Cómo elegir el test adecuado para comparar curvas de supervivencia. Med Clínica (Barc). 2006;127:96-9.
https://doi.org/10.1157/13090265
Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F,Sottotetti F, et al. Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: amulticenter retrospective cohort study. Clin Breast Cancer. 2017;17:601-10.
https://doi.org/10.1016/j.clbc.2017.04.002
Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, et al. Long-term survivor characteristics in HER2- positive metastatic breast cancer from registHER. Br J Cancer. 2014;110:2756-64.
https://doi.org/10.1038/bjc.2014.174
Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2- positive metastatic breast cancer. Breast Cancer Res Treat. 2016;159:367-74.
https://doi.org/10.1007/s10549-016-3933-6
Clark GM, Sledge GW Jr, Osborne CK, Mc Guire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5:55-61.
https://doi.org/10.1200/JCO.1987.5.1.55
Leivonen MK, Kalima TV. Prognostic factors associated with survival after breast cancer recurrence. Acta Oncol Stockh Swed. 1991;30:583-6.
https://doi.org/10.3109/02841869109092422
Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
https://doi.org/10.1186/1471-2407-7-153
Robledo Abad JF, Caicedo Mallarino JJ, DeAntonioSuárez R. Análisis de sobrevida en una cohorte de 1328 pacientes con carcinoma de seno. Rev Colomb Cir. 2005;20:4-20.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
